glp-1 obesity drug news october 2025 ISPOR 2025: Exploring reasons for discontinuation The Obesity-Drug Revolution Is Stalling
Description
These complications are related to malnutrition, dehydration, electrolyte imbalances and blood sugar fluctuations with diabetes
PubMed, Kulanuwat, Sirikul, et al
These important negative data support the hypothesis that even in a weight-reduced state from peak obesity, the DVC GLP-1R and amylin receptors theoretically remain as continued viable drug targets for sustaining weight loss
They go by the names of Ozempic, Mounjaro, and Trulicity those are the best-selling GLP-1 drugs, accounting for 70% of sales in 2023
Am J Physiol-Regul Integr Comp Physiol (2016) 310:R88595
